Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12790MR)

This product GTTS-WQ12790MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12790MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8100MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ4170MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ11074MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ11482MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ10312MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ14260MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ13840MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ2454MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 157
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW